The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
pH-Dependent Adsorption Release of Doxorubicin on MamC-Biomimetic Magnetite Nanoparticles
Abstract
New biomimetic magnetite nanoparticles (hereafter BMNPs) with sizes larger than most common superparamagnetic nanoparticles were produced in the presence of the recombinant MamC protein from Magnetococcus marinus MC-1 and functionalized with doxorubicin (DOXO) intended as potential drug nanocarriers. Unlike inorganic magnetite nanoparticles, in BMNPs the MamC protein controls their size and morphology, providing them with magnetic properties consistent with a large magnetic moment per particle; moreover, it provides the nanoparticles with novel surface properties. BMNPs display the isoelectric point at pH 4.4, being strongly negatively charged at physiological pH (pH 7.4). This allows both (i) their functionalization with DOXO, which is positively charged at pH 7.4, and (ii) the stability of the DOXO-surface bond and DOXO release to be pH dependent and governed by electrostatic interactions. DOXO adsorption follows a Langmuir-Freundlich model, and the coupling of DOXO to BMNPs (binary biomimetic nanoparticles) is very stable at physiological pH (maximum release of 5% of the drug adsorbed). Conversely, when pH decreases, these electrostatic interactions weaken, and at pH 5, DOXO is released up to ∼35% of the amount initially adsorbed. The DOXO-BMNPs display cytotoxicity on the GTL-16 human gastric carcinoma cell line in a dose-dependent manner, reaching about ∼70% of mortality at the maximum amount tested, while the nonloaded BMNPs are fully cytocompatible. The present data su…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“these BMNPs display larger sizes (~40 nm) compared to most commercial chemically synthesized magnetic nanoparticles (MNPs) (≤ 30 nm)”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [5]
In the citing paper
“Therefore, these MamC-mediated BMNPs have been proposed as efficient nanocarriers [5,6,14,15] of a number of molecules offering crucial advantages over the use of inorganically synthesized magnetic nanoparticles to this end.”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [5]
In the citing paper
“MamC confers new surface properties to these BMNPs, in particular, an isoelectric point (pI) at pH 4.4 which allows functionalization based on electrostatic interactions and drug release being pH dependent.”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [5]
In the citing paper
“remaining attached to the nanoparticles and forming a nanocomposite (95 wt% magnetite + 5 wt% MamC)”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [5]
In the citing paper
“MamC-mediated biomimetic nanoparticles (here referred as BMNPs) have demonstrated their potential as promising drug nanocarriers [5,6,14,15]”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [5]
In the citing paper
“(2) high saturation magnetization”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [5]
In the citing paper
“(1) a higher blocking temperature while being superparamagnetic at room temperature”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [5]
In the citing paper
“their advantage over inorganic magnetic nanoparticles is that biomimetic ones show novel properties which make them promising nanocarriers [4,5,6].”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [5]
In the citing paper
“However, BMLs have a biomimetic core with the MamC protein strongly adhered to its surface [5] while IMLs have a core with a free surface.”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [5]
Citations
Cites
Iron Oxide Nanoparticles for Magnetically-Guided and Magnetically-Responsive Drug Delivery
Estelrich, J., Escribano, E., Queralt, J., & Busquets, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16048070 · Cited by 532
Research works printed but not linked: 46
- 10.1021/jp104580t · DOI
- 10.1016/j.mser.2013.04.002 · DOI · Paper page
- 10.1166/jnn.2015.9585 · DOI
- 10.1039/c2cs15260f · DOI
- 10.1038/nrmicro842 · DOI
- 10.3109/17435391003690531 · DOI
- 10.1016/j.biomaterials.2007.07.051 · DOI
- 10.3390/ijms140815977 · DOI
- 10.1002/adfm.201703326 · DOI
- 10.1016/j.jmmm.2009.02.077 · DOI
- 10.1016/j.biomaterials.2016.12.013 · DOI
- 10.1002/adfm.200600448 · DOI
- 10.1074/jbc.M211729200 · DOI
- 10.1007/s00253-014-6326-y · DOI · Paper page
- 10.1074/jbc.273.9.5086 · DOI
- 10.1039/b810061f · DOI
- 10.1021/la4008334 · DOI
- 10.1039/C5NR05826K · DOI
- 10.3390/ma6052026 · DOI
- 10.1007/128_2007_3 · DOI
- 10.1097/FPC.0b013e32833ffb56 · DOI
- 10.1093/annonc/mdf118 · DOI
- 10.1097/CAD.0b013e32803d36fe · DOI
- Von Smoluchowski, M. In Handbuch der Elektrizitt und des Magnetismus; Greatz, L., Ed. J.A. Barth: Leipzig, Germany, 1921; Vol. 2, p 366.
- 10.1021/ja01269a023 · DOI · Paper page
- 10.1016/0378-5173(86)90170-5 · DOI
- 10.1021/ja02242a004 · DOI · Paper page
- 10.1021/la803562e · DOI
- 10.1039/b210712k · DOI
- 10.1039/C5NR00733J · DOI
- 10.1098/rsfs.2016.0068 · DOI
- 10.3390/ijms140714550 · DOI
- 10.1002/smll.201202843 · DOI
- 10.1021/acs.jpcc.7b12561 · DOI
- 10.2320/matertrans.M2014184 · DOI
- 10.1186/s12932-017-0044-1 · DOI
- 10.1016/j.jpcs.2016.08.019 · DOI
- 10.1134/S0020168512040127 · DOI
- 10.1016/j.jsb.2016.03.001 · DOI
- 10.1021/acs.cgd.6b01643 · DOI · Paper page
- 10.1039/C5TB01524C · DOI
- 10.1006/jcis.1997.5239 · DOI
- 10.1016/j.jconrel.2011.01.024 · DOI
- 10.1016/j.ejmech.2008.09.037 · DOI
- 10.1016/0014-4827(84)90699-2 · DOI
- 10.1016/S0065-2571(00)00013-3 · DOI · Paper page
Cited by
Sorted by citations
Garcia-Pinel, B., Jabalera, Y., Ortiz, R., Cabeza, L., Jimenez-Lopez, C., Melguizo, C., & Prados, J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060589 · Cited by 40
Self-citation
Metadata
- Authors
- García Rubia, G., Peigneux, A., Jabalera, Y., Puerma, J., Oltolina, F., Elert, K., Colangelo, D., Gómez Morales, J., Prat, M., & Jimenez-Lopez, C.
- Affiliations
- Dipartimento di Scienze della Salute, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy
- Laboratorio de Estudios Cristalográficos, IACT (CSIC-Universidad de Granada), Avda. Las Palmeras, 4, 18100 Armilla, Spain
- Venue
- Langmuir
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-05
- Volume
- 34
- Issue
- 45
- Pages
- 13713-13724
- ISSN
- 0743-7463
- 1520-5827
- Cited by
- 53
- References
- 1
- Language
- en
- Funders
- European Regional Development Fund (CGL2016-76723, CGL2013-46612)
- Ministerio de Econom?a y Competitividad (CGL2013-46612, CGL2016-76723)
- Universidad de Granada (UCE-PP2016-05)
- Universit? degli Studi del Piemonte Orientale
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
